Equity Profile

RVMD

Revolution Medicines, Inc.

Health CareBiotechnology$31.7B

May6Wed

Post-Earnings Recap

ReportedQ1-2026After Close4:02 PM EDT

Revolution Medicines Misses on EPS, Stock Up 2.62%

Metric	Actual	Expected	Surprise
EPS	$-2.29	$-1.84	-24.86%
Revenue	—	$2M	—

management commentary, guidance changes, and full analysis available with Pro.

Revolution Medicines Misses on EPS, Stock Up 2.62%

Key Numbers

Metric	Actual	Expected	Surprise
EPS	$-2.29	$-1.84	-24.86%
Revenue	—	$2M	—

Management Commentary

Tone: Unknown

No transcript is on record, and the analysis is based on numerical results only.

What It Means

Revolution Medicines reported a larger-than-expected loss per share, missing analyst expectations. Despite this, the stock rose by 2.62%, which may indicate that investors are looking past the earnings miss or are optimistic about future developments. The lack of revenue data and management commentary leaves some uncertainty about the company's current performance and future outlook.

Company Snapshot

Revolution Medicines, Inc. is a biotechnology company focused on developing targeted therapies for cancer treatment....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of the company's profitability and financial health.

-$1.84

Revenue

Revenue figures provide insight into the company's sales performance and market demand for its products.

$2M

Wall Street expectations, options signals, track record, and call prep available with Pro.

Original Pre-Earnings Preview

Context

Company Snapshot

Revolution Medicines, Inc. is a biotechnology company focused on developing targeted therapies for cancer treatment. With a market cap of $31 billion, it plays a significant role in the health care sector, particularly in the development of innovative treatments that could improve patient outcomes.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

Avg EPS Surprise

-12.50%

Avg Stock Reaction

-0.14%

Last Quarter Recap

In the last quarter, Revolution Medicines reported an EPS of -$1.86, which was worse than the expected -$1.56. The stock reacted negatively, dropping 1.52% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts are expecting a challenging quarter with a consensus EPS of -$1.84 and minimal revenue of $2 million. The market is closely watching for any signs of improvement in financial performance.

Bull Case

If the company can exceed EPS expectations and show stronger revenue growth, it could signal a turnaround in its financial health, leading to a positive market reaction.

Bear Case

Conversely, if the company misses its EPS and revenue targets again, it may raise concerns about its long-term viability and lead to further declines in stock price.

Key Metrics to Watch

EPS

-$1.84

Earnings per share is a key indicator of the company's profitability and financial health.

Revenue

$2M

Revenue figures provide insight into the company's sales performance and market demand for its products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will the EPS come in better than the expected -$1.84?

A better-than-expected EPS could indicate improving operational efficiency and investor confidence.

What revenue figures can the company report this quarter?

Revenue performance will be crucial in assessing market demand for its products and overall business health.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for a revenue surprise given recent advancements in product development that could drive sales.

Supporting Evidence

The options market is pricing a 7.71% move, suggesting expectations for volatility that may not align with actual performance.

Insider selling of $18 million could indicate confidence in upcoming performance, contrary to bearish sentiment.

Key Risk

If revenue exceeds $5 million, it could significantly shift market sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is critical as it follows a series of misses, and the market is looking for signs of recovery.

Bull Confirmed If

An EPS of -$1.70 or better, along with revenue exceeding $5 million, would confirm the bull case.

Bear Confirmed If

An EPS worse than -$1.96 and revenue below $2 million would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±7.71%

Historical Avg

±2.5%

Pricing rich

The options market is pricing in a significant move of about 7.71%, indicating that traders expect volatility around the earnings report.

Options are pricing ±7.2% while RVMD has averaged ±2.5% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.5%

30d HV

113.3%

Calls (213K)P/C Ratio: 0.23Puts (100K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich in Health Care

n=30

Fade rate: 4 of 18 (22%)

This setup has occurred 30 times across Health Care in the last 2 years. 14 of 18 (78%) held or extended their move within 5 days — this setup typically holds direction. The average absolute 1-day move is 6.8%, with a raw directional average of +3.0% (modestly positive historical bias).

Edge

Insider Activity

Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.

Bought

$0.00

0 sh

0 insiders

Sold

$18.0M

120,000 sh

1 insider

Net

$18.0M

Net selling

Most Active Insiders· 1 open-market trade

See RemarksGOLDSMITH MARK A
$18.0M
Net selling

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Revolution Medicines beats expectations, history suggests a potential average one-day move of +3.0%, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations, the stock may see muted reactions as investors await further guidance.

Miss

Should the company miss expectations, history suggests an average one-day move of -0.54%, indicating a negative market response.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on product pipeline advancements and their expected impact on revenue.
2Management's commentary on cost management and operational efficiency.
3Insights into market demand for their therapies and any new partnerships.
4Any guidance on future earnings and revenue expectations.
5Responses to analyst questions regarding competitive positioning in the biotechnology space.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

May4

GRABReported

Grab Holdings Limited

RecapView

May4

GBDCReported

Company Snapshot

Revolution Medicines, Inc. is a biotechnology company focused on developing targeted therapies for cancer treatment....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of the company's profitability and financial health.

-$1.84

Revenue

Revenue figures provide insight into the company's sales performance and market demand for its products.

$2M

Wall Street expectations, options signals, track record, and call prep available with Pro.

Original Pre-Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

Avg EPS Surprise

-12.50%

Avg Stock Reaction

-0.14%

Last Quarter Recap

In the last quarter, Revolution Medicines reported an EPS of -$1.86, which was worse than the expected -$1.56. The stock reacted negatively, dropping 1.52% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts are expecting a challenging quarter with a consensus EPS of -$1.84 and minimal revenue of $2 million. The market is closely watching for any signs of improvement in financial performance.

Bull Case

If the company can exceed EPS expectations and show stronger revenue growth, it could signal a turnaround in its financial health, leading to a positive market reaction.

Bear Case

Conversely, if the company misses its EPS and revenue targets again, it may raise concerns about its long-term viability and lead to further declines in stock price.

Key Metrics to Watch

EPS

-$1.84

Earnings per share is a key indicator of the company's profitability and financial health.

Revenue

$2M

Revenue figures provide insight into the company's sales performance and market demand for its products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will the EPS come in better than the expected -$1.84?

A better-than-expected EPS could indicate improving operational efficiency and investor confidence.

What revenue figures can the company report this quarter?

Revenue performance will be crucial in assessing market demand for its products and overall business health.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for a revenue surprise given recent advancements in product development that could drive sales.

Supporting Evidence

The options market is pricing a 7.71% move, suggesting expectations for volatility that may not align with actual performance.

Insider selling of $18 million could indicate confidence in upcoming performance, contrary to bearish sentiment.

Key Risk

If revenue exceeds $5 million, it could significantly shift market sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is critical as it follows a series of misses, and the market is looking for signs of recovery.

Bull Confirmed If

An EPS of -$1.70 or better, along with revenue exceeding $5 million, would confirm the bull case.

Bear Confirmed If

An EPS worse than -$1.96 and revenue below $2 million would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±7.71%

Historical Avg

±2.5%

Pricing rich

The options market is pricing in a significant move of about 7.71%, indicating that traders expect volatility around the earnings report.

Options are pricing ±7.2% while RVMD has averaged ±2.5% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.5%

30d HV

113.3%

Calls (213K)P/C Ratio: 0.23Puts (100K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich in Health Care

n=30

Fade rate: 4 of 18 (22%)

Edge

Insider Activity

Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.

Bought

$0.00

0 sh

0 insiders

Sold

$18.0M

120,000 sh

1 insider

Net

$18.0M

Net selling

Most Active Insiders· 1 open-market trade

See RemarksGOLDSMITH MARK A
$18.0M
Net selling

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Revolution Medicines beats expectations, history suggests a potential average one-day move of +3.0%, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations, the stock may see muted reactions as investors await further guidance.

Miss

Should the company miss expectations, history suggests an average one-day move of -0.54%, indicating a negative market response.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on product pipeline advancements and their expected impact on revenue.
2Management's commentary on cost management and operational efficiency.
3Insights into market demand for their therapies and any new partnerships.
4Any guidance on future earnings and revenue expectations.
5Responses to analyst questions regarding competitive positioning in the biotechnology space.